Share information
251.70 €
+3.07 %
29/05/2026 17:39
+3.07 %
Open
High
Low
Volume
245.10 €
252.70 €
244.50 €
1,063,598
Latest News
19-May-2026
BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data
07-May-2026
UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
03-May-2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)